trending Market Intelligence /marketintelligence/en/news-insights/trending/yv-fv6xo1jjy6vwpw-xsmw2 content esgSubNav
In This List

XBiotech adds board member

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


XBiotech adds board member

Austin, Texas-based XBiotech Inc. said Jan-Paul Waldin was elected to the board and appointed to the audit and compensation committees.

Waldin has been a long-time adviser to the biopharmaceutical company.

With Waldin's appointment, the company has regained compliance with a Nasdaq listing rule regarding board composition.

XBiotech develops antibodies for treating diseases such as cancer, inflammatory conditions, and vascular diseases.